FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048082956> ?p ?o ?g. }

• W2048082956 endingPage "556" @default.
• W2048082956 startingPage "548" @default.
• W2048082956 abstract "This article reports on recent advances on metastatic breast cancer. Detection, prognostic factors, predictors of response to therapy and therapy, with particular regard to targeted therapies, were examined.Unlike current guidelines that yet do not routinely recommend intensive clinical-instrumental post-operative follow-up of breast cancer patients, relatively large data collected in the last decades have shown that an intensive post-operative follow-up with 'dynamic evaluation' of a suitable tumour marker panel precedes a few months as average the clinical and/or instrumental sign of a pending relapse in most relapsed patients and largely limits the use of the common instrumental examinations.Disease-free interval (DFI)<or=24 months, adjuvant chemotherapy, liver and distant soft tissue involvement or DFI>24 months and disease confined to bony skeleton are prognostic factors more often correlated with relatively poor or prolonged survival, respectively. Estrogen receptor (ER) expression in primary tumour and at the relapse correlates strongly with response to salvage hormone therapy and data from large trials showed that 38-59% of ER and/or PR+ post-menopausal patients had clinical benefit from first line tamoxifen or aromatase inhibitors. An inverse correlation of ER with epidermal growth factor receptor (EGFR) has been found. The co-expression of HER-2/neu and/or elevated serum HER-2/neu protein level were associated with a low rate and shorter duration of response of ER+ patients to first line hormone therapy. Accordingly, ER-EGFR- compared with ER-EGFR+ tumours are usually more responsive to endocrine therapy. High class III beta-tubulin expression or fall in insulin-like growth factor binding protein-3 (IGFBP-3) from baseline levels have been found to significantly predict resistance to chemotherapeutic agents.Liposomes as carrier of doxorubicin (Caelix, Evacet, Myocet) is one approach to decrease the anthracycline-related cardiac toxicity. Weekly paclitaxel or docetaxel and oral formulation of vinorelbine and 5-fluorouracil (5-FU) (capecitabine) provide new effective and well tolerated options that reach greater dose intensity and cumulative dose than with the conventional schedules. As to the so called 'tailored' or targeted therapies, the more potent and highly selective third generation of aromatase inhibitors (letrozole, anastrozole, exemestane) targeting ER+ tumours by estrogen deprivation, challenge tamoxifen as current standard first line therapy in postmenopausals. One pilot study showed that stimulation of cellular immunity by the addition of beta-interferon-interleukin-2 sequence in patients on clinical benefit on first line tamoxifen significantly prolonged median overall survival (OS) and duration of response compared to that observed in similar patients only treated with tamoxifen. Trastuzumab, a humanised monoclonal antibody to extracellular domain of HER-2, plus conventional chemotherapy has become a standard of care for women with overexpressing HER-2 tumours. Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor (VEGF) that in refractory metastatic breast cancer doubled the response rate of capecitabine although it did not affect survival. Finally, the so called 'oligometastatic' and a few stage IV diseases are conditions amenable to be rendered with no evidence of disease (NED) after local surgery and/or radiation. In both, as well as in complete responders to chemotherapy, minimal residual disease (m.r.d.) likely continues to be present. Recent data suggest that 'biological' therapy (immunomodulators and/or retinoids with or without hormone therapy), might be suitable to be successfully tested in these patients as maintenance treatment given soon after local intervention or chemotherapy." @default.
• W2048082956 created "2016-06-24" @default.
• W2048082956 creator A5010347660 @default.
• W2048082956 creator A5012863436 @default.
• W2048082956 creator A5024706525 @default.
• W2048082956 creator A5031053541 @default.
• W2048082956 creator A5043158470 @default.
• W2048082956 creator A5056157710 @default.
• W2048082956 creator A5067532512 @default.
• W2048082956 creator A5069958818 @default.
• W2048082956 creator A5074072927 @default.
• W2048082956 creator A5074119720 @default.
• W2048082956 creator A5081012227 @default.
• W2048082956 date "2006-11-01" @default.
• W2048082956 modified "2023-10-16" @default.
• W2048082956 title "Metastatic breast cancer: an updating" @default.
• W2048082956 cites W1525318852 @default.
• W2048082956 cites W1589316426 @default.
• W2048082956 cites W1810933484 @default.
• W2048082956 cites W1836239578 @default.
• W2048082956 cites W1848530042 @default.
• W2048082956 cites W1862306466 @default.
• W2048082956 cites W1911376378 @default.
• W2048082956 cites W1913585306 @default.
• W2048082956 cites W1946759281 @default.
• W2048082956 cites W1948956899 @default.
• W2048082956 cites W1950270470 @default.
• W2048082956 cites W1964680430 @default.
• W2048082956 cites W1964694809 @default.
• W2048082956 cites W1980585910 @default.
• W2048082956 cites W1981454586 @default.
• W2048082956 cites W1985209327 @default.
• W2048082956 cites W1992487388 @default.
• W2048082956 cites W2000523470 @default.
• W2048082956 cites W2007203367 @default.
• W2048082956 cites W2009614326 @default.
• W2048082956 cites W2009995818 @default.
• W2048082956 cites W2011481133 @default.
• W2048082956 cites W2012227742 @default.
• W2048082956 cites W2017022511 @default.
• W2048082956 cites W2034580051 @default.
• W2048082956 cites W2035484878 @default.
• W2048082956 cites W2040527029 @default.
• W2048082956 cites W2042908520 @default.
• W2048082956 cites W2062105189 @default.
• W2048082956 cites W2065165455 @default.
• W2048082956 cites W2071173730 @default.
• W2048082956 cites W2073379232 @default.
• W2048082956 cites W2074493587 @default.
• W2048082956 cites W2080681938 @default.
• W2048082956 cites W2081602653 @default.
• W2048082956 cites W2087256498 @default.
• W2048082956 cites W2089726740 @default.
• W2048082956 cites W2090254460 @default.
• W2048082956 cites W2092318330 @default.
• W2048082956 cites W2104367773 @default.
• W2048082956 cites W2110036563 @default.
• W2048082956 cites W2111648388 @default.
• W2048082956 cites W2112927798 @default.
• W2048082956 cites W2123732467 @default.
• W2048082956 cites W2124061625 @default.
• W2048082956 cites W2126559635 @default.
• W2048082956 cites W2129958055 @default.
• W2048082956 cites W2132723220 @default.
• W2048082956 cites W2136704455 @default.
• W2048082956 cites W2138921844 @default.
• W2048082956 cites W2139112723 @default.
• W2048082956 cites W2141217952 @default.
• W2048082956 cites W2143050099 @default.
• W2048082956 cites W2150805833 @default.
• W2048082956 cites W2153534452 @default.
• W2048082956 cites W2161550802 @default.
• W2048082956 cites W2169073956 @default.
• W2048082956 cites W2170743583 @default.
• W2048082956 cites W2176579253 @default.
• W2048082956 cites W2228069427 @default.
• W2048082956 cites W2270877465 @default.
• W2048082956 cites W2290185180 @default.
• W2048082956 cites W2290869449 @default.
• W2048082956 cites W2318605753 @default.
• W2048082956 cites W2414480807 @default.
• W2048082956 cites W2415944205 @default.
• W2048082956 cites W4237553706 @default.
• W2048082956 cites W4240875418 @default.
• W2048082956 doi "https://doi.org/10.1016/j.biopha.2006.07.086" @default.
• W2048082956 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16950593" @default.
• W2048082956 hasPublicationYear "2006" @default.
• W2048082956 type Work @default.
• W2048082956 sameAs 2048082956 @default.
• W2048082956 citedByCount "105" @default.
• W2048082956 countsByYear W20480829562012 @default.
• W2048082956 countsByYear W20480829562013 @default.
• W2048082956 countsByYear W20480829562014 @default.
• W2048082956 countsByYear W20480829562015 @default.
• W2048082956 countsByYear W20480829562016 @default.
• W2048082956 countsByYear W20480829562017 @default.
• W2048082956 countsByYear W20480829562018 @default.
• W2048082956 countsByYear W20480829562019 @default.

• next